6830

oxandrolone

Phlogenzym is a combination of two complementary enzymes and trypsin bromelain in combination with Rutoside. Enzymes are absorbed through the intestine intact molecules claim resorption. Contacting blood transport proteins into the bloodstream. Subsequently, migrating but bloodstream, accumulate in the area of the pathological process, irrespective of localization in the body. Trypsin, bromelain and promote rapid cell splitting “fragments” n metabolic products of the inflammatory process, and restores rutin permeability of vascular walls, resulting in a reduction of edema and hematoma. . At the same enzymes that are part of the drug, and implement their activity by the anti-inflammatory, immunomodulatory, fibrinolytic, antiagregatnogo, decongestant action, acting on a complex pathophysiological processes .
Phlogenzym improves the oxandrolone functional state of the blood cells and the vascular wall; reduces the viscosity of the blood and the risk of blood clots in blood vessels, helps dissolve clots already formed. It improves the microcirculation, resulting in faster dissolve swelling and bruising. decreases pain.
Phlogenzym improves microcirculation in the foci of chronic inflammation, increases the delivery of oxygen and nutrients (blood supply), thus stimulating repair processes in chronic diseases and in the postoperative period.
Phlogenzym improves blood circulation of the bronchi and lung tissue in chronic respiratory diseases, including those caused by smoking; liquefies phlegm, improves the function of the ciliated epithelium of the bronchi drainage and restores function.
Phlogenzym increases the effectiveness of antibiotic therapy.

Indications
Surgery: in the treatment of post-operative complications, dentistry and plastic surgery (abscess, thrombosis, adhesion); in order to prevent disease, lymph edema and microcirculation disorders, burns.
Traumatology: in the treatment of damaged tendons and ligaments, sports injuries.
Angiology: in the treatment of acute deep vein thrombosis, thrombophlebitis of superficial veins, postthrombophlebitic disease, obliterating atherosclerosis of lower limb arteries and . other chronic arteriopathies
. Urology: in the treatment of acute and chronic inflammation of the urogenital tract: cystitis, urethritis, cystopyelitis, prostatitis
Gynecology: in the treatment of acute and chronic inflammatory diseases of the pelvic organs (adnexitis, salpingo); vascular complications of menopause. To reduce the frequency and severity of complications of hormone replacement therapy.
Cardiology: in the treatment of coronary heart disease, prevention of angina attacks.
Gastroenterology: in the treatment of hepatitis.
Rheumatology: in the treatment of rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, rheumatic soft tissue.

Contraindications
Individual intolerance. Congenital oxandrolone or acquired bleeding disorders (eg, hemophilia). The experience of childhood is absent.

The caution (only after consultation with your doctor)
Pregnancy, lactation. Hemodialysis.

Dosing and Administration
Inside, at least 30 minutes. before eating, not chewing, washing down with water (200 ml). Adults:
With the purpose of treatment Phlogenzym take 3 tablets 3 times a day for 2 weeks if the doctor has not been appointed for a longer period of treatment for prevention Phlogenzym recommended at a dose of 2 tablets 3 times a day for 2 weeks.
Changing the receiving rate and the dosage of the drug is possible only after consultation with your doctor.

Side effects
Phlogenzym well tolerated by patients. In some cases, there may be more frequent stools, change in stool consistency and smell, which quickly cease with temporary reduction of dosage of the drug.Occasionally allergic reactions may occur (skin rash, itching), which disappears after discontinuation of treatment. When using the drug were observed: nausea, flatulence, abdominal pain, headache, dizziness, rash, general weakness. You may receive a temporary feeling of overcrowding in the intestine. This can be prevented by dividing the daily dose into more single doses.

Overdose
No cases of overdose is unknown.

The interaction with other drugs
cases of incompatibility with other drugs was observed. Application Flogenzima conjunction with antibiotics increases the effectiveness of antibiotic therapy.

Specific guidance
in the case of infectious processes Phlogenzym not a substitute for antibiotics.
In the case of aggravation of the disease while recommended temporary dose reduction and should see a doctor.
The drug is not doping, and has no negative effect on driving and performance of work requiring a high rate of mental and physical reactions.
Patients suffering from diabetes, it should oxandrolone be noted that each tablet contains 0.015 bread units.

Product form
The tablets are packaged in blisters to 20 pcs. and placed in cartons of 2, 5 and 10 blisters with enclosed instructions for use. Package 800 includes tablets tablets are not packed in blisters placed  with embedded instructions.

6838

oxandralone

No data on acute or chronic overdose . In healthy volunteers, intranasal administration of 2 mg fluticasone propionate twice daily for 7 days had no effect on the function of the hypothalamic-pituitary-adrenal system (doses 20 times higher than therapeutic). Use of the drug in doses higher than those recommended for a long period of time can lead to temporary suppression of adrenal function.
In such patients, treatment of fluticasone propionate should be continued at the doses needed to control symptoms; restore adrenal function takes a few days, its monitoring is carried out by measuring the cortisol level in the plasma.

The interaction with other drugs
Because of the very low concentrations of fluticasone propionate in plasma after administration of oxandralone andralone clinically significant interactions are very unlikely.
Ritonavir  is able to much increase, the plasma concentration of fluticasone propionate, whereby dramatically reduced levels of cortisol in human serum, there systemic side effects including Cushing’s syndrome and adrenal suppression. Inhibitors  enzyme system cytochrome  produce negligible (erythromycin) and minor (ketoconazole) increase fluticasone propionate plasma concentrations, which do not entail any significant reduction in serum cortisol concentrations. However, caution should be exercised with the concomitant use  inhibitors of cytochrome  enzyme system (eg, ketoconazole) and fluticasone propionate in view of a possible rise in the plasma concentration of the latter.

Special instructions and precautions for the use of
drug is indicated only for intranasal use.
Without medical supervision  should not be constantly used for more than 6 months.
In the long-term use requires regular monitoring of adrenocortical function.
There are reports of the manifestation of systemic effects when using nasal glucocorticosteroids very high doses for a prolonged time. These effects are much less likely than with oral dosage forms of corticosteroids, and may vary among individual patients and also between different glucocorticosteroids.
Full effect fluticasone propionate nasal spray can occur only after several days of treatment. To achieve maximum therapeutic effect is necessary to adhere to a regular patterns of use.
Care should be taken when transferring patients from systemic glucocorticosteroid therapy for the treatment of nasal spray fluticasone propionate, if there is reason to believe a violation of adrenal function. In most patients, nasal spray fluticasone propionate eliminates the symptoms of seasonal allergic rhinitis, but in some cases, at very high concentrations in the air of allergens, may need additional treatment.
Additional treatment may be required for the relief of ocular manifestations against the background of a successful treatment of seasonal allergic rhinitis.
In the post-registration monitoring reported oxandralone cases the occurrence of systemic effects of corticosteroids, such as Cushing’s syndrome and adrenal suppression, with concomitant use of fluticasone propionate and ritonavir.
Therefore, the simultaneous use of ritonavir and fluticasone propionate should be avoided unless the potential benefit to the patient exceeds the possible risk of systemic corticosteroid side effects.

Effects on ability to drive vehicles, mechanisms
In clinical studies, no data on the effect of the drug on the ability to drive vehicles and other mechanisms, but consider the side effects, which can cause the drug.

Product Form
Spray nasal dosage 50 .mu.g / dose.
Each vial is provided with a metering device. Per vial and a metering device worn adapter for intranasal administration. The vial is further provided with a cap to protect the adapter from dust.
Each vial with oxandralone a metering device, an adapter and a protective cap (mounted) and instructions for medical use is placed in a cardboard box.

http://localgid.net/manufacturer/maxpro/

oxandrolone cycle

Following intranasal administration at a dose of fluticasone propionate 200mkg / day. maximum plasma concentration equilibrium is not quantitatively defined in the majority of patients (up less than 0.01 ng / ml). The highest plasma concentration was recorded at 0,017 ng / ml. The direct absorption from the nasal cavity is unlikely due to the low water solubility and most of drug ingestion.

Absolute oral bioavailability is low (less than 1%) by a combination of incomplete absorption from the gastrointestinal tract and the active first-pass metabolism through the liver. Total systemic absorption, thus, extremely low. Distribution Fluticasone propionate has a high volume of distribution at steady state (approximately 318 L). Communication to plasma proteins is high (91%). MetabolismFluticasone propionate is displayed rapidly from the systemic circulation predominantly by hepatic metabolism to form inactive carboxylic acid by oxandrolone cycle isoenzyme of cytochrome P450. The metabolism of ingested fraction fluticasone propionate in the first pass through the liver in the same manner. Excretion Excretion fluticasone propionate is linear over a dose range of from 250 to 1000 g and characterized by a high plasma clearance. Maximum plasma concentration is reduced by approximately 98% within 3-4 hours, and only at very low concentrations in plasma terminal half-life was observed 7,8 h Renal clearance of fluticasone propionate is negligible (less than 0.2%), and an inactive metabolite. – carboxylic acid – less than 5%. Fluticasone propionate and its metabolites are mostly excreted in bile via the intestine. Indications for prevention and treatment of seasonal and perennial allergic rhinitis.

Contraindications for use
Hypersensitivity to fluticasone propionate or any other component of the drug; Children under 4 years old.

Carefully

  • Simultaneous treatment with strong inhibitors isoenzyme, such as ketoconazole and ritonavir may cause increasing concentration of fluticasone propionate in plasma.
  • When applied simultaneously with other dosage forms of corticosteroids.
  • If you have infection of the nasal cavity or paranasal sinuses. Thus infectious diseases of the nose requires appropriate treatment, but are not a contraindication to the use of a nasal .
  • After recently undergone surgery or injury to the nose to the nasal cavity or in the presence of ulceration of the nasal mucosa.

Pregnancy and lactation
Pregnant and lactating women drug oxandrolone cycle can be given only in cases where the expected benefit to the patient is greater than any possible risk to the fetus or child.

Dosing and Administration
Intranasal only.
You need to use the drug on a regular basis to achieve full therapeutic effect. The maximum therapeutic effect may be achieved after 3-4 days of treatment.

Adults and children over 12 years old for prophylaxis and treatment of seasonal and perennial allergic rhinitis 2 injections into each nostril once a day 1, preferably in the morning (200 mg per day). In some cases it is possible to apply to 2 injections into each nostril two times daily (400 mg per day) for a short time to achieve control of symptoms, after which the dose can be reduced. The maximum daily dose – 400 g (not more than four injections in each nostril).

Specific patient groups elderly The usual adult dose. Children from 4 to 12 years for the prevention and treatment of seasonal and perennial allergic rhinitis by injection of 1 s (50 mcg) in each nostril 1 times a day, preferably in the morning. In some cases, it may require the appointment of 1 injection into each nostril 2 times a day. The maximum daily dose -. 200 g (not more than 2 injections in each nostril) The use of the inhaler before use should be carefully shake the bottle, take it, placing the index and middle fingers . on both sides of the tip, and the thumb – a bedplate for the first use of a drug or a break in its use of more than 1 week, check the serviceability sprayer: send a tip by itself, produce a few clicks, until the tip of a small cloud appears not. Next, you need to clean the nose (blow your nose).Close one nostril and put the tip into the other nostril. Tilt oxandrolone cycle your head slightly forward while holding the vial upright. Then. should begin to breathe in through the nose and by continuing to inhale, to produce a single finger tap to spray the drug. Exhale through the mouth. Repeat the procedure for a second spray into the same nostril, if necessary. Next, repeat the above procedure completely, insert the tip into the other nostril. After use, the tip should be wet with a clean cloth or handkerchief and close the cap. The sprayer should be washed at least 1 time per week. To do this, carefully remove the tip and rinse it in warm water. Shake off excess water and leave to dry in a warm place. Avoid overheating. Then gently install the tip into place at the top of the vial. Wear protective cap. If clogged nozzle hole, the tip should be removed in the manner described above and leave for some time in the warm water. Then rinse under cold water, dry and put on a bottle again. You can not clean the hole with a pin or other sharp object tip.

 

Side effects
Adverse events reported below are listed according to the anatomical and physiological classification and frequency of occurrence. Very often, frequently and infrequently occurring adverse events were mainly established on the basis of the clinical study.
The phenomena that occur rarely and very rarely, mostly identified from spontaneous reports. In the formation of the incidence of adverse events, the background rates in the placebo group were not taken into account, as they were generally comparable with the group of active treatment. Immune system : very rarely – hypersensitivity reactions (including bronchospasm, rash, swelling of face and tongue , anaphylactic reactions), anaphylactoid reactions. nervous system : often . – headache, a feeling of unpleasant taste and odor The appearance of headache, unpleasant taste and smell have also been reported with other nasal sprays. From a sight organ : very rarely – glaucoma , increased intraocular pressure, cataract. The causal relationship between intranasal receiving fluticasone propionate and these events in clinical trials lasting up to 1 year has not been revealed. The respiratory system, organs, thoracic and mediastinal disorders : very often – nosebleeds, often – dryness in the nasal cavity and pharynx, irritation of the nasal cavity and pharynx (reported as with other oxandrolone cycle nasal preparations); very seldom – nasal septum perforation (reported when receiving intranasal corticosteroids).